Bristol Myers Squibb - Investors

Latest News

December 27, 2024

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications

December 23, 2024

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

December 23, 2024

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Latest Events

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

December 3, 2024 08:00 AM ET

Citi’s 2024 Global Healthcare Conference

Webcast

November 19, 2024 09:30 AM GMT

Jefferies London Healthcare Conference

Speaker(s):

David V. Elkins, Executive Vice President and Chief Financial Officer

Webcast

November 11, 2024 10:00 AM ET

Guggenheim’s Inaugural Healthcare Innovation Conference

Speaker(s):

Samit Hirawat, MD, Executive Vice President, Chief Medical Officer, Global Drug Development
Robert Plenge, MD, Ph.D., Executive Vice President, Chief Research Officer

Webcast